Michal Ayalon - Kamada Vice President - Research & Development
| KMDA Stock | ILA 2,121 23.00 1.10% |
President
Dr. Michal Ayalon was appointed Vice President Research Development at Kamada Ltd effective January 30, 2019. Her work experience includes the following roles Head of Research Development at 89bio Ltd, Project Champion at Teva Pharmaceutical Industries Ltd, Vice President of Research Development at Galmed Pharmaceuticals Ltd and employee at Immune Pharmaceuticals, Inc, BioLine RX Ltd and Compugen Ltd since 2019.
| Tenure | 5 years |
| Phone | (972) 8 9406472 |
| Web | www.kamada.com |
Kamada Management Efficiency
Kamada's management efficiency ratios could be used to measure how well Kamada manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Ran Kril | Elbit Systems | 52 | |
| Nati Somekh | Tower Semiconductor | 48 | |
| David Stark | Teva Pharmaceutical Industries | 54 | |
| Itzhak Edrei | Tower Semiconductor | 58 | |
| Hafrun Fridriksdottir | Teva Pharmaceutical Industries | 57 | |
| Jonathan Ariel | Elbit Systems | 62 | |
| Sven Dethlefs | Teva Pharmaceutical Industries | 54 | |
| Yehuda Vered | Elbit Systems | 65 | |
| Oren Shirazi | Tower Semiconductor | 53 | |
| Gary Saunders | Tower Semiconductor | 54 | |
| Ilan Rabinovich | Tower Semiconductor | 61 | |
| Brendan OGrady | Teva Pharmaceutical Industries | 52 | |
| Gianfranco Nazzi | Teva Pharmaceutical Industries | 50 | |
| Yehoshua Yehuda | Elbit Systems | 55 | |
| Yoram Shmuely | Elbit Systems | 62 | |
| Eliyahu Kalif | Teva Pharmaceutical Industries | 50 | |
| Mark Sabag | Teva Pharmaceutical Industries | 52 | |
| Zeev Gofer | Elbit Systems | 66 | |
| Edgar Maimon | Elbit Systems | 64 | |
| Marco Racanelli | Tower Semiconductor | 56 | |
| Ilan Pacholder | Elbit Systems | 64 | |
Management Performance
| Return On Equity | -0.058 | |||
| Return On Asset | -0.0023 |
Kamada Leadership Team
Elected by the shareholders, the Kamada's board of directors comprises two types of representatives: Kamada inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kamada. The board's role is to monitor Kamada's management team and ensure that shareholders' interests are well served. Kamada's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kamada's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pnina Strauss, Vice President - Inhalation programs & IP | ||
| Itzhak Krinsky, Director | ||
| Lilach Topilsky, Chairman of the Board | ||
| Ari Shamiss, Director | ||
| Barak Bashari, Vice President - Operations | ||
| Eran Schenker, Vice President - Medical Director | ||
| Tuvia Shoham, Independent Director | ||
| Eran Nir, Chief Officer | ||
| Hanni Neheman, VP Sales | ||
| Michal Stein, Vice President and Medical Director for Immunology | ||
| Ariella Raban, VP HR | ||
| Shani Dotan, Vice President of Human Resources | ||
| Yael Brenner, Vice President - Quality | ||
| Abraham Havron, Independent Director | ||
| Ruth Wolfson, Senior Vice President - Scientific Affairs | ||
| Shmuel Rubinstein, Director | ||
| Naveh Tov, Vice President-Clinical Development and Medical Director for Pulmonary Diseases | ||
| Jon Knight, VP Operations | ||
| Michael Berelowitz, Director | ||
| David Tsur, Co-Founder and Deputy Executive Chairman | ||
| Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D | ||
| Leon Recanati, Chairman of the Board | ||
| Jonathan Hahn, Director | ||
| Gwen Melincoff, Director | ||
| Chaime Orlev, Chief Financial Officer | ||
| Michal Ayalon, Vice President - Research & Development | ||
| Yifat Esq, Gen Legal | ||
| Amir London, Chief Executive Officer | ||
| Estery GilozRan, Independent Director | ||
| Eitan Kyiet, Vice President - Business Development |
Kamada Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kamada a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.058 | |||
| Return On Asset | -0.0023 | |||
| Profit Margin | (0.09) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 636.38 M | |||
| Shares Outstanding | 44.8 M | |||
| Shares Owned By Insiders | 18.50 % | |||
| Shares Owned By Institutions | 32.04 % | |||
| Price To Book | 1.13 X | |||
| Price To Sales | 5.37 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Kamada Stock
When determining whether Kamada offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kamada's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kamada Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kamada Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kamada. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Kamada Stock refer to our How to Trade Kamada Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.